Search

Vericel Corp

Suletud

SektorTervishoid

43.17 2.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.09

Max

43.2

Põhinäitajad

By Trading Economics

Sissetulek

13M

6.3M

Müük

9M

77M

P/E

Sektori keskmine

88.125

57.366

Aktsiakasum

0.04

Kasumimarginaal

8.136

Töötajad

398

EBITDA

8.5M

5.6M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+48.16% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-148M

2.2B

Eelmine avamishind

40.6

Eelmine sulgemishind

43.17

Uudiste sentiment

By Acuity

100%

0%

329 / 340 Pingereas Healthcare

Vericel Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. aug 2026, 20:02 UTC

Correlated Moves

Vericel Corp shares are declining amid broader market pressures, reflecting negative sentiment from disappointing sales growth and guidance from Walmart Inc.

19. aug 2026, 23:26 UTC

Vericel Corp shares are lower in after-market trading, reflecting ongoing weakness. The stock remains near the lower end of its one-month range.

18. aug 2026, 19:26 UTC

Vericel Corp shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains up since Monday's close.

13. aug 2026, 19:43 UTC

Vericel Corp shares are lower today, reflecting ongoing weakness below the 20-day moving average and near the lower end of their one-month range.

11. aug 2026, 19:46 UTC

News

Vericel Corp shares are higher as analysts maintain a "Moderate Buy" consensus, with HC Wainwright's target at $70 and Truist raising its target to $58.

10. aug 2026, 19:46 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting a broader market decline and volatility amid uncertainty over the Federal Reserve's interest rate policy.

7. aug 2026, 19:16 UTC

Correlated Moves

Vericel Corp's shares rise, supported by gains in the ARK Genomic Revolution ETF and Russell 2000 Index, despite earlier fluctuations in trading.

6. aug 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares declined during Thursday's session, tracking broader market trends. The stock remains near the lower end of its one-month trading range.

5. aug 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting broader market trends as the Russell 2000 Index declines. The stock remains below its 20-day moving average.

3. aug 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31. juuli 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30. juuli 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29. juuli 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28. juuli 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27. juuli 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24. juuli 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22. juuli 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21. juuli 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20. juuli 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Võrdlus sarnastega

Hinnamuutus

Vericel Corp Prognoos

Hinnasiht

By TipRanks

48.16% tõus

12 kuu keskmine prognoos

Keskmine 62.67 USD  48.16%

Kõrge 72 USD

Madal 58 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Vericel Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat